Cell Therapy in European Union: Market Size, Businesses & Forecast 2026

The cell therapy industry in the European Union comprises highly innovative medical treatments involving the administration of living cells to prevent, diagnose, or treat diseases by replacing or repairing damaged tissues. The sector is moving toward scaled manufacturing automation, decentralized point-of-care models, and complex autologous or allogeneic bioprocessing networks. According to data compiled by the European Medicines Agency (EMA) Committee for Advanced Therapies (CAT), product-related regulatory evaluation pipelines remained active through 2026, building upon cumulative totals like 306 positive opinions adopted for advanced therapy initial procedures and variations by early 2026

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Cell Therapy in European Union industry cover?

Cell therapy in the European Union is officially classified under Advanced Therapy Medicinal Products (ATMPs). This distinct therapeutic category covers Somatic Cell Therapy Medicinal Products (CTMPs) and Tissue Engineered Products (TEPs), alongside Gene Therapy Medicinal Products (GTMPs). The sector covers both autologous therapies, which use a patient's own modified cells, and allogeneic therapies, which utilize healthy donor cell lines.

• •Regulated specifically under Regulation (EC) No 1394/2007, which established the overarching regulatory framework for all advanced therapies across member states.
• •Differentiated from standard blood transfusions or bone marrow transplants by involving substantial manipulation of cells or utilizing cells not intended for the same essential function.
• •Includes advanced chimeric antigen receptor T-cell (CAR-T) therapies, which fall under the cell or gene therapy classification depending on the genetic modification method.

Who operates in the industry and how is it structured?

The European market structure features a mix of multinational biopharmaceutical corporations, mid-sized specialist biotechnology companies, and extensive academic or non-profit clinical centers. Due to the high complexity of the cell processing pipeline, commercial operators heavily rely on Contract Development and Manufacturing Organizations (CDMOs) and dedicated specialized logistics providers. The network is concentrated around prominent biomedical clusters in Western and Northern Europe.

• •Relies on a rigid 'vein-to-vein' logistical loop that necessitates tightly controlled cryogenic supply chains to maintain cell viability between extraction and re-infusion.
• •Commercialization is concentrated, with major international pharmaceutical companies managing the final centralized distribution across EU hospitals.
• •Supported by specialized life science consultants and engineering firms, such as Progress Life Sciences, who assist developers with complex Good Manufacturing Practice (GMP) alignment.

What drives demand in the industry?

The primary driver of the cell therapy industry is the high volume of unmet medical needs in oncology, hematological malignancies, and rare genetic diseases. Additionally, the EU's shifting demographic profile toward an aging population accelerates the demand for regenerative medicine to address degenerative conditions. Expanded access is also propelled by collaborative public funding initiatives and pilot programs tailored to support non-profit or academic researchers.

• •The presence of an estimated 27 million to 36 million individuals living with rare diseases across EU member states, of which roughly 80% have a genetic origin.
• •Increased adoption of European Medicines Agency (EMA) support mechanisms like the PRIME (Priority Medicines) scheme, which helps accelerate development timelines for therapeutic breakthroughs.
• •Expansion of institutional patient registries and post-market real-world data networks that allow health technology assessment bodies to evaluate long-term therapeutic efficacy.

Who are the notable companies in the industry?

The European market is highly competitive, featuring a prominent presence of global pharmaceutical conglomerates operating advanced manufacturing sites within the region, alongside localized biotechnology firms. These commercial operators handle the logistics, regulatory submissions, and commercial rollout of highly specialized cell therapies. Companies navigate a landscape marked by strategic acquisitions and manufacturing partnerships to increase batch production volumes.

• •Novartis AG maintains extensive operations across Europe, managing foundational marketing authorizations for established cell-based treatments.
• •Bristol Myers Squibb Company operates as a key regional provider with approved cell therapy lines, actively securing expanded indications within the EU market.
• •Gilead Sciences, Inc. drives high volume through its specialized cell therapy subsidiary, delivering oncological immunotherapies throughout Europe.
• •Pfizer Inc. continues to anchor its advanced therapeutic research and distribution footprint deeply within multiple European Union member territories.

What are the recent trends and outlook?

Recent developments showcase steady progression in regulatory evaluations and authorization expansions across the European Union. Automation of cell manufacturing processing equipment is increasingly implemented to decrease human error and cut steep processing costs. Additionally, the industry is transitioning toward decentralized manufacturing configurations to shorten turnaround times for highly time-critical autologous therapies.

• •The European Commission officially issued a centralized marketing authorization to the cell therapy Zemcelpro (dorocubicel) on August 25, 2025, targeting adult hematological malignancies.
• •The EMA Committee for Advanced Therapies (CAT) registered a cumulative total of 306 positive opinions for ATMP evaluations and variations between 2009 and February 2026.
• •Implementation of rapid microbiological testing methods, aligned with updated European Pharmacopoeia standards, to safely shorten the batch release cycle of short-shelf-life products.

How is the industry regulated?

Regulatory enforcement is highly centralized under the European Medicines Agency (EMA), specifically through the Committee for Advanced Therapies (CAT), which performs the scientific assessment of cell therapies. Following a CAT recommendation, the European Commission issues a legally binding marketing authorization valid across all EU and EEA member states. Manufacturers must comply with stringent Good Manufacturing Practice (GMP) requirements tailored to advanced therapies.

• •EudraLex Volume 4, Part IV contains the specific, legally binding GMP requirements for ATMPs, which underwent critical concept revisions to align with sterile processing expectations.
• •The European Pharmacopoeia (Ph. Eur.) implemented rigorous updates, including Monograph 3186 and Chapter 5.34, to formalize exact biosafety and testing criteria for cell products.
• •Enforcement of strict chain-of-identity and contamination control strategies (CCS) to ensure autologous donor cells are never cross-contaminated during the manufacturing loop.

Government, statistical and trade sources used for this Claight analysis.

• European Medicines Agency (EMA) Committee for Advanced Therapies (CAT) Quarterly Report, March 2026 ·
• European Medicines Agency (EMA) Annual Report 2025 ·
• European Parliament and Council Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products ·
• European Pharmacopoeia (Ph. Eur.) Regulatory Updates 2025